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OBJECTIVE: To evaluate the effect of low dose methotrexate alone or in combination with glucocorticoid treatment
on titanium implant osseointegration.
METHODS: Groups of 6–8 adult New Zealand White rabbits were treated for 18 weeks with saline (control),
methotrexate, glucocorticoid, or methotrexate plus glucocorticoid. The animals received a titanium implant in the
tibia at week 6. Lumbar spine and tibia bone mineral densities were analyzed before and after treatment.
Histomorphometric analysis of bone cortical thickness, total bone area around the implant, and % of bone to
implant contact was performed.
RESULTS: After 18 weeks, the change in the bone mineral density in the lumbar spines and tibias in the
methotrexate group was comparable to the control group (0.035 vs. 0.055 g/cm
2 and 0.021 vs. 0.041 g/cm
2,
respectively). In contrast, both the glucocorticoid group and glucocorticoid plus methotrexate group had significant
reductions at both sites. Histomorphometric analysis of the tibia in the control and methotrexate groups revealed
no significant changes in cortical thickness (133 vs. 126 mm), total bone area around the implant (33 vs. 30%), or
bone to implant contact (40 vs. 38%). In contrast, glucocorticoid group had significant reductions compared to
controls in tibia cortical thickness (99 vs. 133 mm), total bone area around the implant (24 vs. 33%), and bone to
implant contact (27 vs. 40%). Similar reductions were observed in the glucocorticoid plus methotrexate group.
CONCLUSIONS: Our results demonstrate that low dose methotrexate treatment does not affect titanium implant
osseointegration, suggesting that this therapy is safe for surgical procedures requiring a titanium implant.
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INTRODUCTION
Bone implants are a valuable tool for the reconstruction of
tissue affected by trauma or inflammatory diseases and for
orthodontic anchorage. The success of endosseous implants
is dependent on osseointegration, a cicatricial process of
implant/bone interaction defined histologically as direct
bone apposition on the implant surface with nearly no
interposition of soft tissue that leads to bone-to-implant
fixation.
1 Titanium is an excellent material for bone implants
due to its biocompatibility, augmented resistance to corro-
sion, lack of toxicity on macrophages and fibroblasts, and
reduced inflammatory response in peri-implant tissues.
2
However, osseointegration also requires the integrity of
the bone remodeling process, which is influenced by
various factors. Issues affecting osseointegration include
the properties and geometry of the implant, implant surface
treatment and coating, host bone bed,
3 mechanical stability
and loading conditions,
4 and the use of adjuvant treat-
ments.
5,6 In particular, non-steroidal anti-inflammatory
therapies like selective COX-2 inhibitors,
7 glucocorticoids
(GC), cyclosporin A,
8 and other immunosuppressants,
which are drugs commonly used in rheumatologic patients,
have deleterious effects on osseointegration.
Low dose methotrexate (MTX) is an antirheumatic drug
widely prescribed to patients with rheumatoid arthritis (RA).
However, its effect on bone metabolism remains controversial.
Low doses of this drug in patients with active RA had a
protective effect on bone metabolism from controlling the
disease activity.
9 In fact, MTX therapy has been reported to
inhibit generalized bone loss in patients with RA.
10
Conversely, a deleterious effect on bone metabolism has been
described in RA patients
11 and in animals.
12 There is only a
single case report on the effect of MTX on osseointegration,
which describes a successful rehabilitation of a titanium
implant in an elderly patient with severe osteoporosis and
chronic polyarthritis whoset r e a t m e n ti n c l u d e dM T X .
13 In
contrast, GC, which is an anti-inflammatory drug frequently
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1055prescribed in association with MTX for rheumatologic
patients, was found to negatively affect osseointegration of
titanium implants.
14-16 The distinction of the deleterious effect
of these drugs on bone metabolism is hampered by their
concomitant use with multiple therapies in autoimmune
diseases. Additionally, systemic conditions per se, such as RA
and other inflammatory conditions, may also affect this
process.
17,18
In this context, experimental models provide a unique
condition to discriminate between the effects induced by the
disease itself and those caused by the therapy. Therefore, we
have evaluated whether low dose MTX influences bone
density and histomorphometric parameters of peri-implant
bone healing around titanium implants placed in the tibia in
a rabbit experimental model.
MATERIALS AND METHODS
Animals and treatments
All experimental procedures performed on animals were
in accordance with UFAW (The Universities Federation for
Animals Welfare) and the Animal Ethics Committee of
COBEA (Brazilian College of Experimental Animals). This
protocol was approved by the Institutional ethics committee
# 453/05. Male New Zealand adult rabbits 16 weeks old and
weighing 2.67¡0.067 kgwere divided into fourgroupsof6–8
rabbits each. The animals were kept in individual cages with
food and water ad libitum and treated as follows: subcuta-
neous saline (0.3 mL, control group); intramuscular metho-
trexate (3 mg/kg/week, MTX group)
12, subcutaneous
glucocorticoid (0.35 mg/kg methylprednisolone 3 times/
week, GC group),
19 MTX (3 mg/kg/week) plus GC (0.35
mg/kg methylprednisolone 3 times/week, MTX+GC group).
Endosseous implant model
The implant surgery was performed 6 weeks after the
initial drug administration. The animals were anesthetized
with a mixture of xylazine (5 mg/kg) associated with
ketamine (50 mg/kg) by the intramuscular route. After
trichotomy, the skin was cleansed, an incision of approxi-
mately 2 cm was made, and the tibia was exposed by blunt
dissection. A unicortical implant bed was prepared and a
screw-type, commercially pure titanium implant with a
rough surface, 8.5 mm in length and 3.75 mm in diameter
(Conexa ˜o Sistema de Protese Ltda, 1–2 mm porosity), was
placed such that the screw thread was completely perpen-
dicular into the bone cortex.
16 Soft tissues were replaced and
sutured. A single dose of Enrofloxacin was administered
just before surgery and dipyrone was given for three days
afterwards.
Densitometric evaluation
Bone density was measured by dual-energy X-ray
absorptiometry (DXA) with a densitometer (QDR 2000
Hologic, Waltham, MA) in high-resolution mode using the
‘‘small animals’’ software supplied by the equipment
manufacturer. The technique was standardized by position-
ing the anesthetized rabbits such that the lumbar spine
(vertebrae L4-L5) and the proximal portion of the tibia that
was not operated on (right) was analyzed. The region of
interest was defined as the same where the implant was
inserted but in the contralateral tibia. The initial assessment
was performed on the first day of the experiment and the
final at end of the treatment (week 18). Results are expressed
as mean ¡ SE of bone mineral density (BMD) variation
(DBMD = final BMD - initial BMD).
Analysis of bone parameters
After the animals were euthanized (week 18), the left tibia
(implanted) and right tibia (non-operated) were removed
and fixed in 4% neutral buffered formalin for 14 days. The
specimens were prepared for non-decalcified histology.
20
Briefly, pieces were washed in running water for 24 hours,
dehydrated in an ascending series of ethanol (40% to 100%),
and subsequently embedded in methyl metacrylate blocks.
Sections (80 microns) were obtained and stained with
toluidine blue as described previously.
16
Bone cortical thickness, tibia size (diameter), ratio of bone
to implant contact, total bone area of the tibia section, and
peri-implant bone density were analyzed by light micro-
scopy. Images were captured and digitalized with Image
Pro Plus 6 (Media Cybernetics, Bethesda, MD). The cortical
thickness (mm) was determined as the mean of multiple
measurements of the non-operated right tibia taken at
30 mm intervals along the tibia perimeter.
Osseointegration was observed via light microscopy as
direct bone (toluidine blue-stained) deposition on the
implant surface without any other detectable tissue inter-
posed. The total bone area of the tibia section was evaluated
by software that determines the area of bone tissue (BT)
stained with toluidin blue present in the total area [tibia +
implant (TA, mm
2)] and expresses it as the percentage of
total bone area = BT/TA 6100.
24 The ratio of bone to
implant contact (BIC) was calculated from the measurement
of the total perimeter of the implant (TPI) and all the
osseointegrated spaces around the implant (OSI), both of
which were obtained manually, and expressed as percent
bone to implant contact (% of BIC = OSI/TPI 6100). Two
specialists blinded to the treatments acquired all the bone
parameter data.
STATISTICAL ANALYSIS
Bone parameter results were analyzed by repeated
measures ANOVA and compared with the Newman-Keuls
test (when normal distribution was detected). The ratio of
bone to implant contact was expressed as the median and
the comparisons between groups were carried out with the
Mann-Whitney U test. Based on the ratio of bone to implant
contact difference between groups, the observed power of
analysis was 77% (b risk =23%). Results are expressed as
mean ¡ SE and the chosen level of significance was 0.05.
RESULTS
General outcomes
Gain of body weight was comparable among the groups
(control, 0.82¡0.15 kg; MTX, 1.18¡0.24 kg; GC, 0.58¡0.10 kg
and GC+MTX, 0.65¡0.22 kg, p=0.105). No adverse gastro-
intestinal effects (vomiting or diarrhea) were observed.
Mortality, infection, andwound dehiscencewas not recorded
with this protocol.
Bone mass density variation
Initial bone mass densities were similar among the experi-
mental groups for the lumbar spine (control, 0.269¡0.008 g/
cm
2;M T X ,0 . 2 7 4 ¡0.011 g/cm
2; GC, 0.268¡0.010 g/cm
2;
GC+MTX, 0.284¡0.011 g/cm
2, p=0.674) and tibia (control,
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10560.371¡0.012 g/cm
2;M T X ,0 . 3 8 5 ¡0.008 g/cm
2; GC, 0.387¡
0.011 g/cm
2;G C +MTX, 0.387¡0.011 g/cm
2, p=0.641).
After 18 weeks, control animals had a positive lumbar
BMD variation (DBMD, 0.055¡0.009 g/cm
2 ) comparable to
the MTX group (0.035¡0.015 g/cm
2, p=0.280, Fig. 1A).
However, there was a significant reduction of DBMD in the
GC group (-0.004¡0.012 g/cm
2, p=0.003) and GC+MTX
group (-0.003¡0.012 g/cm
2, p=0.003, Fig. 1A). Tibia DBMD
were also positive and similar in control and MTX groups
(0.041¡0.011 g/cm
2 vs. 0.021¡0.009 g/cm
2, p=0.190), but
significantly decreased in GC (-0.018¡0.008 g/cm
2,




Histomorphometric analysis at 18 weeks revealed that the
cortical thickness was comparable in the control and MTX
groups (133.08¡2.36 vs. 126.24¡2.42 mm, p=0.071). In
contrast, at the final evaluation GC (98.81¡2.28 mm,
p,0.001) and GC+MTX groups (96.41¡3.12 mm, p,0.001)
had significant reductions. In addition, the percentage of
bone tissue around the implant in control and MTX groups
was similar (33.16¡1.29 vs. 30.13¡1.04%, p=0.097)
whereas GC (24.40¡1.51%, p,0.001) and GC+MTX
(25.65¡1.63%, p=0.005) groups had significantly lower
percentages of bone tissue around the implant compared.
The effects of these treatments on the percent of bone to
implant contact (BIC) are summarized in Fig. 2A. Again,
control and MTX groups had comparable values of
osseointegration [median 39.56% (31.63–55.57%) and
37.99% (22.34–42.97%), respectively, p=0.101], while GC
[27.12% (14.53–37.45%), p=0.003] and GC+MTX groups
[31.94% (18.43–46.55%), p=0.03] reduced values. The
osseointegration of titanium implants in rabbit tibia was
observed as direct bone (toluidine blue stained) deposition
on the implant surface without any other detectable tissue
interposed (Fig. 2B & C).
DISCUSSION
The present study is the first to provide compelling
evidence that low dose methotrexate does not have a
deleterious effect on titanium implant osseointegration.
Patients with inflammatory diseases are often treated with
MTX and novel biological therapies are frequently pre-
scribed in combination with this drug.
21 The increase in
quality of life for rheumatologic patients achieved in the last
decade
22 may increase the demand for arthroplasty and
prosthodontic treatments.
The advantage of the present study’s design using normal
rabbits is that we were able to discriminate between the
effects of MTX therapy and those of inflammatory disease
on bone metabolism. Analysis of intracellular signaling
mechanisms in osteoclasts has demonstrated that various
immunomodulatory molecules play a role in the control of
bone metabolism in RA.
23 In addition, there is growing
acceptance of simultaneous therapy in RA with multiple
drugs associated with GC
24 and the present model provides
a clear analysis of the effects of each drug on the
osseointegration process.
Another strength of our study is that we administered
doses equivalent to what is routinely prescribed in the
clinical setting
12 and we treated animals with tibias of
almost complete (94%) length.
25 This allowed us to mini-
mize complications, since long-term therapy with high
cumulative MTX-doses in children is associated with
osteopathy, which is characterized by osteopenia, zones of
calcification, growth arrest lines, and fractures.
26 This
complication seems to be due to intracellular accumulation
of MTX and formation of methotrexate-polyglutamates in
the rapidly growing skeletal structures of infants.
27 MTX-
osteopathy in adult rheumatic disease patients under low
dose therapy is uncommon and restricted to a few case
reports.
11,28 The causal relationship is still under debate
since these five patients had other important risk factors for
Figure 1 - Lumbar spine and tibia BMD variation (DBMD) in
control animals (saline injected), methotrexate (MTX, 3 mg/kg/
week), glucocorticoid (GC, 0.35 mg/kg/week), and GC+MTX.
Panel A: lumbar and Panel B: tibia DBMD after 18 weeks of
treatment. Results are expressed as the mean of 6–8 animals ¡
S.E. *p,0.05 by comparison to control animals by ANOVA
followed by the Newman-Keuls test.
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1057osteoporotic fractures, emphasizing the relevance of the
present study.
29 In addition, the observation period in the
present study was an appropriate exposure time to the drug
considering the comparative life spans of rabbits and
humans,
30,31 which is relevant since MTX-osteopathy in
adults is associated with prolonged periods of therapy.
28,32
Our data confirms and extends previous observations that
low dose MTX does not have a negative effect on BMD in
patients with RA and psoriasis.
32,33 The complete exclusion
of disease interference in our model allows for an accurate
conclusion regarding the lack of a deleterious effect of this
drug on bone mass at either cortical or trabecular sites. In
addition, reproduction of the clinical conditions often
observed in rheumatologic patients revealed that MTX
had no effect on BMD when associated with GC. The
reductions recorded in the GC and GC+MTX groups are
comparable and are attributable to the GC treatment since
this drug can cause rapid bone loss, decreased bone
formation, and increased bone resorption.
34
Our results reveal that MTX treatment preserves cortical
thickness, percent of bone around the implant, and percent
of bone to implant contact (BIC), all of which are histological
criteria for osseointegration, in spite of the limited number
of animals. In contrast to zoledronic acid,
18 MTX was unable
to reverse the deleterious effect of GC. In fact, the previously
reported protective effect of MTX is only seen under
inflammatory conditions when several cytokines and other
chemical mediators such as PGE2, which affect bone cells,
were involved.
35
Together our data suggest that low dose MTX therapy
should be maintained in individuals requiring implant
surgery since this drug does not affect the osseointegration
process.
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